BTIG Reiterates Buy on AC Immune, Maintains $8 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 88.9%

Neg 0% Neu 88.9% Pos 0%

BTIG analyst Thomas Shrader reiterates AC Immune (NASDAQ:ACIU) with a Buy and maintains $8 price target.

Comments

No comments yet. Be the first!